Farm-Holding got into the pharmaceutical cluster
Pharm-Holding will become the fifth resident of the pharmaceutical cluster in PushkinKommersant-SPB newspaper, 27.05.2010
Published on the website pharma2020.ru
The last resident of the pharmaceutical cluster in St. Petersburg has been identified: it will be the company "Pharm-Holding", engaged in the production of peptide drugs. In the near future, the company's management will sign an investment agreement with the administration of St. Petersburg on the construction of a plant that will be located next to four other pharmaceutical sites in Pushkin. According to experts, investments in a unique enterprise for the Russian industry will exceed $ 20 million only at the initial stage. As Kommersant has learned, an investment agreement will be signed in the near future between the administration of St. Petersburg and the management of Pharm Holding on the construction of a research and production complex. According to the application submitted by the company to the St. Petersburg State Institution "Investment Management", the enterprise will be located on 3 hectares in the Pushkin district of St. Petersburg. It is planned that the project will be implemented in the period from 2010 to 2014. As Oleg Granstrom, CEO of Pharm Holding, explained to Kommersant, the project investor at the initial stage will be Pharm Holding itself, which has been fulfilling orders for Russian pharmaceutical companies for several years. In the subsequent stages, he expects to attract industry-specific investors.
The field of activity of Pharm Holding is peptide preparations (obtained from amino acids by synthesis). According to Oleg Granstrom, the company operates in four directions. The first is the production of substances, the second is the production of diagnostic systems, the third is the synthesis of peptides for research by customer companies and the fourth is the production of finished medicines. Medicines that will be produced by Pharm Holding can be used to treat diseases of the central nervous system, in urology and ophthalmology. According to Sergey Shulyak, director of the DSM Group research company, there are no large enterprises specializing in peptide preparations in Russia, despite the prospects of this direction recognized by the scientific community. "The largest pharmaceutical corporations have been buying small biotech companies with promising developments in recent years," Sergey Shulyak shares his observations. According to his estimates, the construction of an enterprise that complies with GMP and GLP standards will cost investors at least $ 20 million.
The director of the company "Pharmexpert – analytics and Consulting" David Melik-Huseynov believes that, despite the statements about the development of innovations voiced at all levels of government, a clear strategy for the development of the pharmaceutical industry has not yet been developed, which makes it difficult to assess the prospects of "Farm Holding". "It is not yet obvious whether the state policy will focus on the construction of generic boxes – factories, or efforts will be made to develop scientific developments, so the project direction looks very risky," Mr. Melik–Huseynov believes. According to him, the most capital-intensive direction for Pharm Holding may be the declared production of diagnostic systems and finished medicines, while the production of pharmaceutical substances is unlikely to be able to be brought to large volumes due to high competition from South-East Asian manufacturers. Mr. Melik-Huseynov believes that the construction of a detailed plant will cost at least $ 30 million. Earlier, four more residents announced their projects, the implementation of which was planned in a pharmaceutical cluster located on the territory of 18 hectares in Pushkin: Geropharm, Biocad, Samson-Med, Neon.
Portal "Eternal youth" http://vechnayamolodost.ru28.05.2010